Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

“…Patients were asked to record the application of the tablet and any adverse events (AEs), and their medication, if applicable, during the first 14 days of treatment at home. The diary period was limited to the first 14 days because it is known from the controlled trials with the SQ Ò grass SLIT tablet that AE incidences are highest on day 1 of treatment and subsequently decline with proceeding treatment [4][5][6][7][8][9][10][11].…”

“…The standardised sublingual grass allergy immunotherapy tablet (SQ Ò grass SLIT tablet) has been developed for sublingual application in patients with grass pollen-induced rhinoconjunctivitis, and has been investigated in more than 5700 patients in controlled clinical trials in Europe and North America [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. It has been approved Europe-wide and was launched in Germany in November 2006.…”

Health-Related Quality of Life and Rhinitis Control Measures in Allergic Rhinitis

“…The RQLQ has been used in many well-powered clinical trials as a secondary outcome both for subcutaneous [38,39] and sublingual immunotherapy [40][41][42][43] in adults and children [44]. These studies have shown that immunotherapy improves HRQoL in allergic rhinoconjunctivitis patients.…”

Recommendations for appropriate sublingual immunotherapy clinical trials

“…In recent years, attempts have been made to have a uniformity in the potency of extracts by expressing the content of allergens in mcg/mL. This has resulted in the ability to perform dose-ranging trials which provided consistent results for grasses in different trials [5,6], but similar data are still needed for other relevant allergens.…”

“…Some studies have clearly shown a dose-dependent effect of SLIT [5,6], indicating robust support in favor of its clinical efficacy. Due to the large number of trials available, several meta-analyses have been carried out (Table 1), with various inclusion criteria such as rhinitis and asthma [7,8], asthma only [9], asthma and/or rhinitis in children [10,11], conjunctivitis [12].…”